Lilly Ventures

Lilly Ventures operates as the global corporate venture capital arm of Eli Lilly and Company, focusing on strategic investments within the biotechnology sector. It seeks to engage innovative biotech companies at their nascent stages, supporting the development of novel therapeutic solutions across a broad spectrum of disease areas. The firm provides financial backing alongside scientific and strategic guidance, aiming to foster advancements that align with the parent company's pharmaceutical research and development goals.

Established by Eli Lilly and Company, Lilly Ventures originated from the strategic imperative to access and nurture external innovation, complementing internal discovery efforts. The parent corporation recognized the critical need to support emerging life science companies, understanding that early-stage ventures often drive groundbreaking scientific discoveries. This approach allows Eli Lilly to remain at the forefront of medical advancements by partnering with promising biotech firms, leveraging their agility and specialized expertise.

Lilly Ventures primarily invests in early-stage biotech companies, which serve as its "customers" or portfolio companies. Its vision is deeply intertwined with Eli Lilly's overarching mission to discover and deliver medicines that improve lives globally. By investing in and collaborating with these early ventures, Lilly Ventures aims to accelerate the translation of cutting-edge science into potential new therapies, ultimately contributing to a healthier future for patients worldwide.